|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 1. Questionnaire on patient satisfaction and potential fears.** | | | | | | |
|  |  | ***I totally agree*** | ***I agree*** | ***I neither agree nor disagree*** | ***I don’t agree*** | ***I strongly disagree*** |
| **Questions on satisfaction with the study** | | | | | | |
| 1) | I was happy to take part in the study. |  |  |  |  |  |
| 2) | It gives me a very good feeling personally, that I was able to contribute to the research about my illness. |  |  |  |  |  |
| 3) | I think that the participation in this study has an additional value on my health. |  |  |  |  |  |
| 4) | Dealing with my illness was an emotionally draining task. |  |  |  |  |  |
| **Questions on study organization, comprehension and quality of informed consent** | | | | | | |
| 5) | The process and the explanation of the study was clear and comprehensible. |  |  |  |  |  |
| 6) | I basically understood why individual study parts were realized. |  |  |  |  |  |
| 7) | I was satisfied with the information about the CHIP-diagnostic. |  |  |  |  |  |
| **Questions on patient education** | | | | | | |
| 8)\* | The CHIP-Positivity was intelligibly explained to me. |  |  |  |  |  |
| 9)\* | The information letter concerning CHIP helped me to have the most important information at hand again after the medical consultation. |  |  |  |  |  |
| 10)\* | I think it’s reasonable that my primary care physician received information about my CHIP-Positivity. |  |  |  |  |  |
| **Questions on potential fears** | | | | | | |
| 11)\* | The presence of CHIP worries me a lot. |  |  |  |  |  |
| 12)\* | Knowing I’m CHIP-positive stresses me out. |  |  |  |  |  |
| 13)\* | I wish I didn’t know that I’m CHIP-positive. |  |  |  |  |  |
| \*Questions 8-13 are only provided to patients who are tested as CHIP positive | | | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | | | |
| **Supplementary Table 2. Genes included in targeted sequencing (myeloid panel)** | | | | |
| ABL1 | CSNK1A1 | IDH2 | PAX5 | **SF3B1** |
| ANKRD26 | CTCF | IKZF1 | PDGFRA | SH2B3 |
| ARID1A | **CUX1** | JAK1 | PHF6 | SMC1A |
| **ASXL1** | CXCR4 | **JAK2** | PIGA | SMC3 |
| ASXL2 | DDX41 | KAK3 | PML | SOS1 |
| ATM | DHX15 | KDM6A | **PPM1D** | SRP72 |
| ATRX | **DNMT3A** | KIT | PRPF40B | **SRSF2** |
| **BCOR** | EED | KMT2A | PTEN | STAG1 |
| **BCORL1** | ELANE | **KMT2D** | RAD21 | STAG2 |
| BRAF | ETNK1 | KRAS | RAF1 | STAT3 |
| BRCC3 | ETV6 | LUC7L2 | RB1 | STAT5B |
| CALR | EZH2 | MECOM | RBBP6 | SUZ12 |
| **CBL** | FANCA | MET | RPS19 | TERC |
| CBLB | FANCL | MPL | RTEL1 | TERT |
| CBLC | FLT | MYC | RUNX1 | **TET2** |
| CCND2 | GATA1 | NF1 | SAMD9 | THPO |
| CDKN2A | GATA2 | NOTCH1 | SAMD9L | **TP53** |
| CEBPA | **GNAS** | NOTCH2 | SBDS | **U2AF1** |
| CHEK2 | **GNB1** | NPM1 | **SETBP1** | U2AF2 |
| **CREBBP** | HNRNPK | NRAS | **SETD2** | WT1 |
| CSF3R | HRAS | NSD1 | SF1 | ZBTP7A |
| CSMD1 | IDH1 | NUP214 | SF3A1 | ZRSR2 |
| Genes in bold are included as required in WHO classification of myeloid malignancies. | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 3. Size of confidence intervals in relation to number of approached versus participating patients.** | | | | | | |
| N p | 50 | 100 | 150 | 200 | 250 | 300 |
| 0.5 | 0.289 | 0.203 | 0.165 | 0.143 | 0.127 | 0.116 |
| 0.6 | 0.284 | 0.199 | 0.162 | 0.14 | 0.125 | 0.114 |
| 0.7 | 0.267 | 0.187 | 0.152 | 0.131 | 0.117 | 0.107 |
| 0.8 | 0.237 | 0.165 | 0.134 | 0.115 | 0.103 | 0.094 |
| 0.9 | 0.185 | 0.127 | 0.103 | 0.088 | 0.078 | 0.071 |
| Abbreviations: N, number of approached patients; p, real participation rate | | | | | | |